Lexicon Pharmaceuticals’ (LXRX) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Monday morning,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Lexicon Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $2.50.

Lexicon Pharmaceuticals Stock Up 3.4 %

LXRX stock opened at $0.34 on Monday. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.83. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. The stock has a market cap of $82.74 million, a P/E ratio of -0.45 and a beta of 1.04. The business’s 50-day moving average price is $0.74 and its 200-day moving average price is $1.16.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in LXRX. Bayesian Capital Management LP bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $31,000. RPO LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $33,000. Renaissance Technologies LLC bought a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at approximately $38,000. Arizona State Retirement System raised its stake in Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 16,136 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 24,615 shares during the period. Institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.